JP2018536697A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536697A5
JP2018536697A5 JP2018534025A JP2018534025A JP2018536697A5 JP 2018536697 A5 JP2018536697 A5 JP 2018536697A5 JP 2018534025 A JP2018534025 A JP 2018534025A JP 2018534025 A JP2018534025 A JP 2018534025A JP 2018536697 A5 JP2018536697 A5 JP 2018536697A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disease
composition according
protein
homeoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018534025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536697A (ja
JP6860575B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/072675 external-priority patent/WO2017071889A1/en
Publication of JP2018536697A publication Critical patent/JP2018536697A/ja
Publication of JP2018536697A5 publication Critical patent/JP2018536697A5/ja
Application granted granted Critical
Publication of JP6860575B2 publication Critical patent/JP6860575B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018534025A 2015-09-23 2016-09-23 神経変性障害の処置に用いられるホメオタンパク質 Active JP6860575B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306482.9 2015-09-23
EP15306482 2015-09-23
PCT/EP2016/072675 WO2017071889A1 (en) 2015-09-23 2016-09-23 Homeoproteins for use in the treatment of neurodegenerative disorders

Publications (3)

Publication Number Publication Date
JP2018536697A JP2018536697A (ja) 2018-12-13
JP2018536697A5 true JP2018536697A5 (https=) 2019-09-05
JP6860575B2 JP6860575B2 (ja) 2021-04-14

Family

ID=54207439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018534025A Active JP6860575B2 (ja) 2015-09-23 2016-09-23 神経変性障害の処置に用いられるホメオタンパク質

Country Status (7)

Country Link
US (2) US20190247461A1 (https=)
EP (2) EP3352777B1 (https=)
JP (1) JP6860575B2 (https=)
CN (1) CN108289929A (https=)
ES (2) ES2895154T3 (https=)
PL (2) PL3960195T3 (https=)
WO (1) WO2017071889A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120676931A (zh) 2023-01-13 2025-09-19 布瑞恩维公司 Engrailed蛋白的稳定水性组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662698A1 (fr) 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
FR2855178B1 (fr) * 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
FR2897780B1 (fr) 2006-02-28 2008-05-23 Centre Nat Rech Scient Utilisation de la proteine a homeodomaine engrailed comme anxiolytique
GB0625321D0 (en) * 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker
FR2926023B1 (fr) 2008-01-09 2010-02-26 Centre Nat Rech Scient Utilisation d'une homoproteine de la famille bicoid pour le traitement du glaucome.
RU2012100903A (ru) * 2009-07-13 2013-08-20 Зе Юниверсити Оф Саррей Терапевтические пептиды, полипептиды и последовательности нуклеиновых кислот
WO2013128239A1 (en) * 2012-02-29 2013-09-06 Centre National De La Recherche Scientifique Use of engrailed for increasing dopamine synthesis by dopaminergic neurons

Similar Documents

Publication Publication Date Title
JP2019524822A5 (https=)
HRP20191055T1 (hr) Terapeutska sredstva za neurodegenerativne bolesti
WO2012080729A3 (en) Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
EP4234568A3 (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
EP3405215A4 (en) METHOD FOR THE TREATMENT OF MORBUS DANON AND OTHER AUTOPHAGIC DISEASES
JP2017509667A5 (https=)
IL262799B1 (en) Synapse proteins as biomarkers and differential diagnosis of Alzheimer's disease and other neurodegenerative disorders
MA50800A (fr) Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
BR112015027682A2 (pt) Uso de sobetirome no tratamento de doenças ou condições associadas com a desmielinização ou mielinização insuficiente
EA201991756A1 (ru) Бисгетероарильные производные в качестве модуляторов агрегации белков
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2017062500A3 (en) Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
EP3672587A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
EP3481465A4 (en) ACTIVE SUBSTANCE RELEASE ARRANGEMENT FOR CARTRIDGE-BASED MEDICINAL PRODUCTS
Kitamura et al. Stress proteins and glial functions: possible therapeutic targets for neurodegenerative disorders
EA201991374A1 (ru) Водорастворимое производное эпиаллопрегнанолона и его применение
MY189740A (en) Butylphthalide-telmisartan heterocomplex, preparation method and application thereof
MX2019004280A (es) Organonitro-sulfoalquilo y compuestos relacionados y composiciones farmacéuticas para uso en medicina.
HRP20260264T1 (hr) Kanabinoidni pripravak i njegova primjena u pripremi lijeka za liječenje neurodegenerativnih bolesti kao što su parkinsonova bolest i alzheimerova bolest
HRP20210361T1 (hr) Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja
EP3639839A4 (en) PEPTIDE WITH ANTIDEPRESSIVE EFFECT AND THERAPEUTIC EFFECT AGAINST ALZHEIMER'S MORBUS
IL259710A (en) Compositions and methods of treatment for mvid and related diseases
JP2016523969A5 (https=)
EA201991753A1 (ru) Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков